Jun Jie Wu

US Patent:

20200230142, Jul 23, 2020

Filed:

Jan 24, 2020

Appl. No.:

16/751288

Inventors:

- Northbrook IL, US
Kenneth K. Iwata - Northbrook IL, US
Gregory J. Riely - New York NY, US
Jun Wu - Buffalo Grove IL, US
Helena Yu - New York NY, US

International Classification:

A61K 31/517
A61K 9/51
A61K 45/06

Abstract:

A novel dosing regimen for erlotinib or a pharmaceutically acceptable salt thereof is described herein. The dosing regimen demonstrates impressive control of central nervous system disease, which is better than that reported with standard dose erlotinib. The use of the novel dosing regimen for treating patients in need thereof, including for controlling formation of metastatic brain, leptomeninges, or CNS lesions in a patient with non-small cell lung cancer (NSCLC) that harbors epidermal growth factor receptor (EGFR) mutation with or without pre-existing brain metastases, is also described herein.

US Patent:

20170273982, Sep 28, 2017

Filed:

Mar 25, 2016

Appl. No.:

15/081273

Inventors:

- Northbrook IL, US
Kenneth K. IWATA - Northbrook IL, US
Gregory J. RIELY - New York NY, US
Jun WU - Buffalo Grove IL, US
Helena YU - New York NY, US

International Classification:

A61K 31/517
A61K 9/51
A61K 45/06

Abstract:

A novel dosing regimen for erlotinib or a pharmaceutically acceptable salt thereof is described herein. The dosing regimen demonstrates impressive control of central nervous system disease, which is better than that reported with standard dose erlotinib. The use of the novel dosing regimen for treating patients in need thereof, including for controlling formation of metastatic brain, leptomeninges, or CNS lesions in a patient with non-small cell lung cancer (NSCLC) that harbors epidermal growth factor receptor (EGFR) mutation with or without pre-existing brain metastases, is also described herein.

US Patent:

20160128322, May 12, 2016

Filed:

Nov 5, 2015

Appl. No.:

14/933876

Inventors:

- New York NY, US
Partha Patra - New York NY, US
Jun Wu - New York NY, US

International Classification:

A01N 25/16
A01N 59/00

Abstract:

The disclosed subject matter relates to a bleach foam formulation, and to methods of use of the bleach foam formulation for the decontamination of surfaces exposed to infectious agents. disclosed subject matter provides a method for the delivery of the bleach foam formulation for the decontamination of surfaces, and specifically for the decontamination of health workers' personal protection suits, exposed to Ebola, SARS or other infectious agents. In certain embodiments, the use of the bleach foam formulation involves the delivery of the bleach foam from distances for the safe disinfection of contaminated surfaces.

Address:

68 Bay 7 St FL 2, Brooklyn, NY 11228

Phone:

7182345837

VIN:

WBXPC93457WF04064

Make:

BMW

Model:

X3

Year:

2007